Use of vonoprazan for management of systemic sclerosis‑related gastroesophageal reflux disease

Tabuchi, Maiko; Minami, Hitomi; Akazawa, Yuko; Ashida, Miwa; Hara, Toshihide; Ichinose, Kunihiro; Kitayama, Moto; Hashiguchi, Keiichi; Matsushima, Kayoko; Yamaguchi, Naoyuki; Takeshima, Fuminao; Kondo, Hisayoshi; Kawakami, Atsushi; Nakao, Kazuwa

doi:10.3892/br.2020.1401

Cited by 11 publications

(6 citation statements)

References 31 publications

(41 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this context, encouraging results were obtained with vonoprazan, an H+/K+ ATPase blocker. SSc patients with GERD refractory to proton-pump inhibitors, experienced a significant improvement of symptoms after treatment with vonoprazan (64). The efficacy and safety of autologous fat grafting for the treatment of skin and peripheral microvascular involvement in SSc was recently established in 25 patients with mouth and/or hand involvement (microstomia, xerostomia, skin sclerosis, Raynaud's phenomenon and long-lasting DUs).…”

Section: Clinical and Experimental Rheumatology 2021mentioning

confidence: 99%

One year in review 2021: systemic sclerosis

Orlandi

Lepri

Damiani

et al. 2021

Clinical and Experimental Rheumatology

View full text Add to dashboard Cite

Systemic sclerosis is a rare and chronic connective tissue disease with a multifaceted pathogenesis characterised by heterogeneous multi-organ clinical manifestations. Every year, many studies contribute to enrich the knowledge on the pathogenesis, organ involvement and treatment of this complex and severe disease. We herein provide an overview on the most relevant contributions published in the literature in 2020.

show abstract

Section: Clinical and Experimental Rheumatology 2021mentioning

confidence: 99%

One year in review 2021: systemic sclerosis

Orlandi

Lepri

Damiani

et al. 2021

Clinical and Experimental Rheumatology

View full text Add to dashboard Cite

show abstract

“…Potassium-competitive acid blocker (P-CAB), a new H + /K + ‐ATPase inhibitor, has been shown to have a longstanding and rapid effect in patients with gastroesophageal reflux disease [ 54 ]. The authors of a recent study believe that vonoprazan positively improves esophageal erosion but has a limited effect on dysphagia [ 55 ].…”

Section: Existing Treatment Methods and Potential Therapeutic Targetsmentioning

confidence: 99%

Esophageal Dysfunction in Systemic Sclerosis: An Update

Yan

et al. 2021

Rheumatol Ther

View full text Add to dashboard Cite

Esophageal motility disorders are prevalent in 90% of patients with systemic sclerosis [scleroderma (SSc)], with an increased mortality rate in patients with severe esophageal involvement. Esophageal smooth muscle damage caused by ischemia, nerve damage, and inflammatory factors may be responsible for discomfort and various complications in these patients. The clinical manifestations are diverse. Most hospitals still use traditional esophageal manometry and 24-h pH monitoring to diagnose esophageal function in patients with SSc. The aim of this review article is to provide an overview of SSc-related esophageal motility disorders and related research progress, including the pathogenesis and clinical features of these disorders and the progress made in endoscopic diagnosis. We also discuss the possible pathogenesis and potential therapeutic targets.

show abstract

“…These potassium-competitive acid blockers inhibit proton pump potassium–exchange and do not depending on gastric acid for activation. One of these medications, known as vonoprazan, is available in Japan and can facilitate the healing of erosive esophagitis and improve reflux symptoms in patients with refractory GERD [45 ▪ ,46,47]. If the diagnostic work-up suggests that oesophageal dysmotility and/or a hypotensive LES is driving the symptoms of refractory reflux, prokinetics may be considered for symptom control [48,49].…”

Section: Upper Gastrointestinal Tract Involvementmentioning

confidence: 99%

Gastrointestinal involvement in systemic sclerosis: pathogenesis, assessment and treatment

Volkmann

2022

Current Opinion in Rheumatology

View full text Add to dashboard Cite

Purpose of reviewThe majority of patients with systemic sclerosis (SSc) will experience involvement of their gastrointestinal over the course of their disease. Despite the high prevalence of gastrointestinal involvement in SSc, the strategies pertaining to the assessment and treatment for this clinical dimension of SSc have historically been limited. However, the present review highlights recent research contributions that enhance our understanding of SSc-GI patient subsets and provides updates on pathogenic mechanisms of disease, assessment and symptom-directed management. Recent findingsIn the past few years, several studies have identified risk factors for more severe gastrointestinal disease in SSc and have provided insight to optimize diagnosis and management of SSc-GI symptoms. This article also provides a review of currently available investigations and therapies for individual SSc-GI disease manifestations and reflects on actively evolving areas of research, including our understanding the role of the gut microbiome in SSc. SummaryHere, we provide important updates pertaining to the risk stratification, assessment, diagnosis and management of SSc patients with gastrointestinal symptoms. These findings provide opportunities to enhance patient care and highlight exciting opportunities for future research.

show abstract

Use of vonoprazan for management of systemic sclerosis‑related gastroesophageal reflux disease

Cited by 11 publications

References 31 publications

One year in review 2021: systemic sclerosis

One year in review 2021: systemic sclerosis

Esophageal Dysfunction in Systemic Sclerosis: An Update

Gastrointestinal involvement in systemic sclerosis: pathogenesis, assessment and treatment

Contact Info

Product

Resources

About